VCs in £3.75m round for Bicycle Therapeutics

Existing backers Atlas Ventures, Novartis Venture Fund, SR One and SV Life Sciences were joined by Astellas Venture Management in the funding round.

The fresh capital will be used to invest in a selection of drug candidates using the company's bicyclic peptide technology platform.

Previous funding
In October 2009, Atlas Venture and Novartis Venture Fund provided seed financing for Bicycle Therapeutics as part of a first round of institutional funding for the firm. In December that year, the firm secured an undisclosed amount of funding from SR One, the independent corporate venture fund of GlaxoSmithKline, and SV Life Sciences.

Company
Founded in 2009 and based in Cambridge, Bicycle Therapeutics is a spinout of the MRC Laboratory of Molecular Biology. The company applies its technology to drug discovery projects in oncology, metabolic and inflammatory diseases, and will make its platform accessible for collaborative research with pharma partners.

People
Sakae Asanuma is president & CEO of Astellas.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• UK / Ireland
• Healthcare
• Expansion
• United Kingdom
• Atlas Venture